Artiva Biotherapeutics said early data showed clinical responses for investigational AlloNK plus rituximab, underscoring the potential for an off-the-shelf outp

Artiva Biotherapeutics said early data showed clinical responses for investigational AlloNK plus rituximab, underscoring the potential for an off-the-shelf outpatient immune reset therapy. The program already holds FDA RMAT designation in autoimmune disease.